← Eichor
Study identifier: NCT06061848 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT

Condition: Allergic Rhinitis Due to Grass Pollen  ·  Sponsor: Lars Olaf Cardell

PhasePhase 2/Phase 3
Planned participants360
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

A national, multicenter, randmised double blind study with parallell arms. 360 patients with grass induced allergic rhinitis will be open randomised 1:2 to 3 years Grazax sublingual immunotherapy or 3 intralymphatic injections with ALK Alutard Timothy. In a second step, the ILIT group will be double blind randomised 1:1 to an intramuscular injection of Vitamin D Vicotrat or placebo, 4 week before the start of the intralymphatic treatment. The primary outcome measure is daily combined symptoms and medication scores during grass pollen season.

This description comes directly from the study's public registry record.

Talk to the study team

Agneta Karlsson, Study nurse  ·  +46 72 580 29 63  ·  agneta.j.karlsson@regionstockholm.se

Laila Hellkvist, MD, PhD  ·  +46 72 469 46 07  ·  laila.hellkvist@regionstockholm.se

Always discuss trial participation with your own doctor first.

Locations (3)

Skåne University Hospital, ENT departmentLund, SwedenNot Yet Recruiting
Örebro University HospitalÖrebro, SwedenNot Yet Recruiting
Karolinska University Hospital, ENT-departmentStockholm, SwedenRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06061848